Makana Therapeutics's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Makana Therapeutics

Latest quarter: $0; Q2 2026 · 1 reports
Last 12 months: $0; Last 4 quarters
vs last quarter: No record; Q2 2026 against the quarter before
First report: Q4 2022; The first quarter a report named it

Lobbying by quarter

Makana Therapeutics lobbying by quarter
Quarter	Amount	Reports
Q4 2022	$80K	1
Q1 2023	$80K	1
Q2 2023	$80K	1
Q3 2023	$30K	1
Q4 2023	$0	1
Q1 2024	$0	1
Q2 2024	$0	1
Q3 2024	$0	1
Q4 2024	$0	1
Q1 2025	$0	1
Q2 2025	$0	1
Q3 2025	$0	1
Q4 2025	$0	1
Q1 2026	$0	1
Q2 2026	$0	1

Policy issues the reports name

Health issues4 reports

A report that names several issues counts once for each.

Who was lobbied

Food & Drug Administration (FDA)4 reports
HOUSE OF REPRESENTATIVES4 reports
SENATE4 reports
Centers For Medicare and Medicaid Services (CMS)3 reports
Health & Human Services, Dept of (HHS)3 reports

Firms it paid

Firm
King & Spalding	$270K	15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

	Filed by		Issues
05/11for Q2	King & Spalding	Under $5,000
04/18for Q1	King & Spalding	Under $5,000
01/19for Q4 2025	King & Spalding	Under $5,000
25/10/20for Q3 2025	King & Spalding	Under $5,000
25/07/21for Q2 2025	King & Spalding	Under $5,000
25/04/18for Q1 2025	King & Spalding	Under $5,000
25/01/14for Q4 2024	King & Spalding	Under $5,000
24/10/18for Q3 2024	King & Spalding	Under $5,000
24/07/22for Q2 2024	King & Spalding	Under $5,000
24/04/19for Q1 2024	King & Spalding	Under $5,000
24/01/16for Q4 2023	King & Spalding	Under $5,000
23/10/19for Q3 2023	King & Spalding	$30K	Health issues
23/07/11for Q2 2023	King & Spalding	$80K	Health issues
23/04/07for Q1 2023	King & Spalding	$80K	Health issues
23/01/18for Q4 2022	King & Spalding	$80K	Health issues